The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia

Abstract

Hypoxia is a common feature of solid tumors that contributes to angiogenesis, invasiveness, metastasis, altered metabolism and genomic instability. As hypoxia is a major actor in tumor progression and resistance to radiotherapy, chemotherapy and immunotherapy, multiple approaches have emerged to target tumor hypoxia. It includes among others pharmacological interventions designed to alleviate tumor hypoxia at the time of radiation therapy, prodrugs that are selectively activated in hypoxic cells or inhibitors of molecular targets involved in hypoxic cell survival (i.e., hypoxia inducible factors HIFs, PI3K/AKT/mTOR pathway, unfolded protein response). While numerous strategies were successful in pre-clinical models, their translation in the clinical practice has been disappointing so far. This therapeutic failure often results from the absence of appropriate stratification of patients that could benefit from targeted interventions. Companion diagnostics may help at different levels of the research and development, and in matching a patient to a specific intervention targeting hypoxia. In this review, we discuss the relative merits of the existing hypoxia biomarkers, their current status and the challenges for their future validation as companion diagnostics adapted to the nature of the intervention.

Mapping the topography of spatial gene expression with interpretable deep learning

“…Just as single-cell transcriptomics of tumor samples led to the identification of numerous clinical and molecular biomarkers [158], we anticipate that spatial variation in gene expression in the TME will also have high clinical relevance. For example, we showed that GASTON extracts gradients in gene expression that correlate with metabolism, the epithelial-mesenchymal transition (EMT) and other hallmarks of the TME which may translate to novel biomarkers for prognostics, treatment outcome prediction, and personalized medicine [28, 57, 44]. Additionally, GASTON introduces a new axis of tumor classification, in which tumors may be further characterized by the variation of distinct tumor processes across spatial gradients; for example, some tumors may have an increasing gradient of aerobic metabolism towards the tumor center (e.g.…”

The Combined Treatment with Ketogenic Diet and Metformin Slows Tumor Growth in Two Mouse Models of Triple Negative Breast Cancer

“…Since well-oxygenated, proliferating cancer cells can be targeted by chemo-, radio-and immunotherapies, our metabolic regimen is a natural candidate for combination with these therapies for synergistic therapeutic effects. Finally, this metabolic regimen may be similarly effective against a broad range of other FDG-PET-positive (glycolytic) tumors in other organs (10,18,71).…”

The value of magnetic resonance blood oxygen level-dependent imaging in evaluating the efficacy of advanced cervical cancer combined with radiotherapy and chemotherapy

“…The BOLD parameters (T2*/R2* values) are related to the concentration of deoxyhemoglobin in local tissue, which can indirectly reflect the oxygen distribution state of the tissue. A high R2* value indicates a high local deoxyhemoglobin concentration, poor local oxygenation, and tissue in a hypoxic state (8,(10)(11)(12)21). High concentration oxygen can improve the dissociation of oxygen in capillary terminals and tissue spaces and cause the ratio of oxygenated-to-deoxyhemoglobin to increase.…”